MiNK Therapeutics (INKT) Stock Forecast & Price Target

MiNK Therapeutics is supported by a compelling ARDS opportunity because no drug has materially moved mortality in 25 years, the late-stage field is thin, and agenT-797 showed a striking 70% vs. 10% 30-day survival comparison in Ph1/2 with no severe CRS or ICANS across 91 patients. Its current ~124-patient placebo-controlled Ph2b uses a rigorous Day-14 alive-and-ECMO-free hierarchy that can roll into a 180- to 270-patient Ph3, while FDA feedback expected before YE26 and a 3Q27 interim provide meaningful de-risking catalysts. Fundamentally, the platform also looks commercially practical: one donor leukopak yields hundreds of doses through a closed 20- to 30-day process, 1Q26 operating expenses were just $2.9M, and the company ended 1Q26 with $9.5M in cash after paying off a $5M convertible note and raising $3M.

MiNK Therapeutics is exposed to substantial clinical and regulatory uncertainty, since negative safety or efficacy findings for agenT-797, including the 3Q27 randomized interim, could force valuation and estimate cuts, while the FDA has not yet agreed the seamless Ph2b/3 design is registrational. Its lead allogeneic iNKT platform has no prior regulatory success, reimbursement for ARDS lacks precedent, and commercialization would require building sales and medical affairs infrastructure despite uncertain market potential. Financially, the company had about $8.8M in cash and cash equivalents at 6/30/26, while operating losses and free cash flow remained deeply negative, implying a likely need for additional equity financing and dilution before profitability.